References
- Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective B-blockers in the treatment of hypertension. High Blood Press Cardiovasc Prev 2005;12:27-35
- Belz GG. Pharmacological differences among angiotensin II receptor antagonists. Blood Press Suppl 2001;2:13-18
- Frishman WH, Saunders E. beta-Adrenergic blockers. J Clin Hypertens (Greenwich) 2011;13:649-53
- Mancia G. Clinical differences among angiotensin II receptor antagonists. Blood Press Suppl 2001;2:19-24
- Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013;13:265-73
- Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
- Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007;61:15-23
- Baker TM, Goh J, Johnston A, et al. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. J Med Econ 2012;15:253-60
- Signorovitch J, Zhang J, Wu EQ, et al. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin 2010;26:849-60
- Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491-9
- Gu Q, Burt VL, Dillon CF, et al. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126:2105-14
- Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012;59:16-21
- Signorovitch JE, Samuelson TM, Ramakrishnan K, et al. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin 2012;28:591-9
- Truven Health Analytics. Ann Arbor, MI.
- Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care 2009;15(2 Suppl):S36-41
- Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44
- Hermans MP, De Coster O, Seidel L, et al. Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study. Blood Press Suppl 2009;1:5-14